Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
  • Publication Type:
    Journal article
  • Publication Sub Type:
  • Authors:
    Abaleke E, Abbas M, Abbasi S, Abbott A, Abdelaziz A, Abdelbadiee S, Abdelfattah M, Abdul B, Abdul Rasheed A, Abdul-Kadir R, Abdulmumeen A, Abdulshukkoor N, Abdusamad K, Abed El Khaleq Y, Abedalla M, Abeer Ul Amna AU, Aboaba A, Abo-Leyah H, Abou-Haggar A, Abouibrahim M, Abraham M, Abraham T, Abraheem A, Abrams J, Abu HJ, Abu-Arafeh A, Abubacker SM, Abung A, Aceampong Y, Acharya D, Acheson J, Acosta A, Acton C, Adabie-Ankrah J, Adam F, Adam M, Adamali H, Adams C, Adams K, Adams R, Adams T, Adamus M, Adcock K, Adebiyi A, Adegoke K, Adell V, Adeni A, Adenwalla S, Adesemoye OA, Adewunmi EO, Adeyemi J, Adeyeye E, Adkins G, Adnan A, Aeron-Thomas J, Afari L, Affleck D, Afnan C, Afolabi D, Afridi M, Agbeko R, Agbo C, Aggarwal S, Aghababaie A, Agwada-Akeru J, Agyapong KA, Ahamed Sadiq S, Ahammed Nazeer MH, Ah-Chuen J, Ahmad M, Ahmed A, Ahmed B, Ahmed F, Ahmed I, Ahmed I, Ahmed L, Ahmed MC, Ahmed MS, Ahmed N, Ahmed N, Ahmed O, Ahmed RA, Ahmed R, Ahmed S, Ahmed S, Ahmed S, Ahmed SH, Ahmed Ali R, Ahmer S, Ail D, Ainsley A, Ainsworth M, Aissa M, Aitchson L, Aitken L, Ajay B, Ajibode A, Ajmi A, Akhtar MN, Akhtar N
  • Publication date:
  • Pagination:
    605, 612
  • Journal:
    The Lancet
  • Volume:
  • Issue:
  • Status:
  • Print ISSN:
© 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Background: Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19. Methods: In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospital with COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once per day by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatment groups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment and were twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants and local study staff were not masked to the allocated treatment, but all others involved in the trial were masked to the outcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) were eligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was 65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomly allocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall, 561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days (rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median 10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days (rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, no significant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24). Interpretation: In patients admitted to hospital with COVID-19, azithromycin did not improve survival or other prespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restricted to patients in whom there is a clear antimicrobial indication. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers Show More
UCL EGA Institute for Womens Health
Div of Infection & Immunity
Renal Medicine
Institute for Global Health
Inst of Clinical Trials &Methodology
Infection, Immunity & Inflammation Dept
Institute for Global Health
Div of Infection & Immunity
Infection, Immunity & Inflammation Dept
Infection & Population Health
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by